Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice.
Sign Up to like & getrecommendations! Published in 2021 at "Pharmacological research"
DOI: 10.1016/j.phrs.2021.105524
Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition, by increasing hepatic low density lipoprotein (LDL) receptor (LDLR) levels, has emerged as a strategy to reduce atherosclerosis by lowering circulating very low density lipoprotein (VLDL)-cholesterol. We hypothesized… read more here.
Keywords: fat activation; inhibition; pcsk9 inhibition; atherosclerosis ... See more keywords
Colesevelam enhances the beneficial effects of brown fat activation on hyperlipidaemia and atherosclerosis development
Sign Up to like & getrecommendations! Published in 2019 at "Cardiovascular Research"
DOI: 10.1093/cvr/cvz253
Abstract: Abstract Aims Brown fat activation accelerates the uptake of cholesterol-enriched remnants by the liver and thereby lowers plasma cholesterol, consequently protecting against atherosclerosis development. Hepatic cholesterol is then converted into bile acids (BAs) that are… read more here.
Keywords: atherosclerosis development; fat activation; cholesterol; brown fat ... See more keywords
Atypically Intense Pharmacologically Induced Brown Fat Activation on FDG PET/CT
Sign Up to like & getrecommendations! Published in 2023 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000004520
Abstract: Abstract Brown fat activation with increased radiotracer localization on FDG PET/CT studies is a well-known phenomenon. Activated brown adipose tissue (BAT) is usually seen in the supraclavicular region, but also in paraspinal and rarely in… read more here.
Keywords: atypically intense; fdg pet; fat activation; brown fat ... See more keywords